The incidence risk of preeclampsia in pregnant women treated with selenium supplementation versus placebo

The incidence risk of preeclampsia in pregnant women treated with selenium supplementation versus placebo: a randomized double-blind placebo-controlled trial

Status

Active, not recruiting

Phases

Phase 2

Study type

Interventional

Source

IRCT

Registry ID

IRCT201702109014N143

Enrollment

158

Registered

2017-02-20

Start date

2017-02-19

Completion date

Unknown

Last updated

2018-02-22

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Pre-eclampsia. Pre-eclampsia, unspecified

Interventions

Intervention 1: Intervention group: Selenium supplementation 100 mgr once a day until the end of pregnancy. Intervention 2: Control group: Placebo once a day until the end of pregnancy.

Treatment - Drugs

Placebo

Intervention group: Selenium supplementation 100 mgr once a day until the end of pregnancy.

Control group: Placebo once a day until the end of pregnancy.

Eligibility

Sex/Gender

Female

Inclusion criteria

Inclusion criteria: Inclusion criteria: Primigravid; first trimester. Exclusion criteria: Using selenium supplementation during past year; using any medications except ferrous sulfate and folic acid; thyroid disease; diabetes; hypertension; infective diseases; diet full of selenium.

Exclusion criteria

Exclusion criteria:

Design outcomes

Primary

Measure	Time frame
Measuring systolic and diastolic blood pressure. Timepoint: before intervention and at the end of pregnancy. Method of measurement: through physical examination.	—

Countries

Iran (Islamic Republic of)

Contacts

Public ContactDr Fatemeh Mohsenpour

Fatemieh Hospital

fatemeh_mohsenpour450@yahoo.com+98 81 3828 3939

Outcome results

None listed

Source: IRCT (via WHO ICTRP) · Data processed: Feb 4, 2026